Targeted Delivery of Liposomal Temozolomide Enhanced Anti-Glioblastoma Efficacy through Ultrasound-Mediated Blood–Brain Barrier Opening

Targeted Delivery of Liposomal Temozolomide Enhanced Anti-Glioblastoma Efficacy through Ultrasound-Mediated Blood–Brain Barrier Opening

Glioblastoma (GBM) is the commonest form of primary brain tumor in the central nervous system, with median survival below 15 months and only a 25% two-year survival rate for patients. One of the major clinical challenges in treating GBM is the presence of the blood–brain barrier (BBB), which greatly...

Full description

Bibliographic Details
Main Authors: Zhuqing Song, Xiuxian Huang, Jieqiong Wang, Feiyan Cai, Ping Zhao, Fei Yan
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Pharmaceutics
Subjects:
glioblastoma
blood–brain barrier
ultrasound
temozolomide
liposome
Online Access:https://www.mdpi.com/1999-4923/13/8/1270

Similar Items

Similar Items